180 Life Sciences Corporate Media Kit

31 Fibrosis Program Patents METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE Country Application No. Date Filed Status Australia 2017248273 16/10/2018 Filed Canada 3020327 05/10/2018 Filed Europe 17779836 05/11/2018 Filed Hong Kong 19128046 12/08/2019 Filed U.S. 62/320,151 08/04/2016 Filed U.S. 16/089,234 27/09/2018 Filed METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING AN IL-33 ANTAGONIST Country Application No. Date Filed Status Australia 2016226414 15/09/2017 Filed Canada 2,978,449 29/02/2016 Filed Europe 16759325 25/09/2017 Filed Hong Kong 18107063.7 30/05/2018 Filed U.S. 15/555,027 15/12/2017 Granted 10/12/2019 US10500273B2 METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING A TNF RECEPTOR 2 ANTAGONIST Country Application No. Date Filed Status Australia 2016226415 18/09/2017 Filed Canada 2,978,431 29/02/2016 Filed Europe 16759326.8 25/09/2017 Filed Hong Kong 18107062.8 30/05/2018 Filed U.S. 15/555,030 31/08/2017 Filed METHOD OF TREATING OCULAR FIBROSIS USING AN IL-33/TNF BISPECIFIC ANTIBODY Country Application No. Date Filed Status U.S. 62/722,263 24/08/2018 Filed METHOD OF TREATING LOCALIZED FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY Country Application No. Date Filed Status U.S. 16/328,979 27/02/2019 Filed Europe 17924768.9 01/04/2019 Filed METHOD OF TREATING SYSTEMIC FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY Country Application No. Date Filed Status U.S. 16/329,013 27/02/2019 Filed Europe 17847574.5 01/04/2019 Filed Hong Kong 62020001194 09/01/2020 Filed METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS INCLUDING DUPUYREN'S WITH ONE OR MORE SPECIFIC HUMAN MMP AND ATNF ANTAGONIST Country Application No. Date Filed Status U.S. 61/845,366 11/07/2013 Filed USES OF IL-33 RECEPTORS ANTAGONIST Country Application No. Date Filed Status U.S. 62/127,157 02/03/2015 Filed 180 Life Sciences Corp. www.180lifesciences.com Q4 2020